Skip to main content

The Alzheimer’s disease market is anticipated to grow at an annualized rate of over 13%, till 2030, claims Roots Analysis

 

Roots Analysis has announced the addition of “Alzheimer's Disease Market (2nd Edition), 2021-2031” report to its list of offerings.

 

Limited treatment options and unmet needs are the key drivers of research activity in this domain. Several industry and non-industry players are presently engaged in developing various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief. Moreover, multiple venture capital firms and other strategic investors have been supporting the research related initiatives of various start-ups. Driven by a rich development pipeline and the efforts of various stakeholders, the market is anticipated to grow at a significant pace in the coming future.

 

To order this 150+ page report, which features 90+ figures, please visit

https://www.rootsanalysis.com/reports/view_document/alzheimers-disease-market/247.html

 

Key Market Insights

 

More than 240 drug candidates for the treatment of Alzheimer’s disease and associated symptoms are currently being investigated

Over 90% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the drugs (60%) are designed for oral administration.

 

190,000+ patients have been enrolled in over 2,000 clinical trials, worldwide

Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of around 40% in the last five years. Of the total number of trials, close to 65% have already been completed, while 25% are active and still recruiting patients.

 

Close to 20,000 articles focused on Alzheimer’s disease and related symptoms have been published since 2017

Several industry and non-industry players engaged in this domain are undertaking numerous initiatives to identify and develop novel therapies for this neurodegenerative condition. Majority (81%) of the articles published by authors affiliated to deemed universities are focused on studying the disease pathology.

 

Several partnerships were established in this domain, during the period 2017-2021

Maximum number of partnerships were observed to be inked in 2018, indicating a recent rise in the interest of various players engaged in this domain. Majority of the deals were reported to be research and development agreements, representing over 34% of the total number of instances.

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/view_document/alzheimers-disease-market/247.html

 

Key Questions Answered

§  Who are the leading industry players involved in the Alzheimer’s disease industry?

§  Which geographies are the most active in conducting clinical trials on therapies for Alzheimer’s disease?

§  Which are the leading funding organizations providing grants in the Alzheimer’s disease industry?

§  Which partnership models are commonly adopted by industry stakeholders in the Alzheimer’s disease industry?

§  How is the current and future market opportunity, related to Alzheimer’s disease, likely to be distributed across key market segments?        

 

The financial opportunity within the Alzheimer’s disease market size has been analyzed across the following segments:

§  Type of Treatment

  • Symptomatic Treatment
  • Disease Modifying Treatment

 

§  Type of Symptomatic Indications

  • Dementia
  • Insomnia
  • Other Psychological Symptoms

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific and RoW’

 

The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the adoption of display library technologies. The report includes detailed transcripts of the discussions held with the following industry experts:

§  Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)

§  Mathias Schmidt (Chief Executive Officer, ArmaGen)

§  Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)

 

 

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/alzheimers-disease-market/247.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.    Squamous Non-Small Cell Lung Cancer Market, 2021-2031

2.    Novel T-Cell Immunotherapies Market, 2021-2030

3.    HER2 Targeting Therapies Market, 2021-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Comments

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...